Data as of Nov 21
| +4.45 / +1.49%|
Biogen Idec, Inc. is a global biotechnology company focused on discovering, developing, manufacturing and marketing therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. Its products include AVONEX, TYSABRI, FAMPYRA, RITUXAN and FUMADERM. AVONEX product is indicated for the treatment of patients with relapsing forms of MS to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations. TYSABRI product is indicated for the treatment of relapsing forms of MS as a monotherapy to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. This product is also used for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation. FAMPYRA product is indicated for the improvement of walking ability in adult patients with MS who have walking disability. FUMADERM product is only approved in Germany and is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom topical therapy is ineffective. RITUXAN product is indicated for treatment of relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) as a single agent; for previously untreated diffuse large B-cell, CD20-positive, NHL in combination with CHOP or other anthracycline-based chemotherapy regimens; and for previously untreated follicular. Biogen Idec was founded on November 12, 2003 and is headquartered in Weston, MA.
|George A. Scangos||Chief Executive Officer & Director|
|Paul J. Clancy||Chief Financial Officer & Executive Vice President|
|Raymond Pawlicki||Chief Information Officer & Senior Vice President|
|Douglas E. Williams||Executive Vice President-Research & Development|
|Spyridon Artavanis-Tsakonas||Chief Scientific Officer & Senior Vice President|